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ABSTRACT
Decoy oligonucleotides have been used for func-
tional sequestering of transcription factors. Efficient
introduction into cells is a prerequisite for the
oligonucleotides to exert their blocking function.
Lipofection is the most widely used technique for
that purpose because of its convenience and relat-
ively high efficiency. However, the transduction effi-
ciency of lipofection largely depends on cell types
and experimental conditions and the introduced nuc-
leotides are not specifically directed to nuclei where
they exert their major function. In the present study,
we designed a new system for transporting oligonuc-
leotides into cell nuclei. The vehicle is composed
of glutathione-S-transferase, 7 arginine residues,
the DNA-binding domain of GAL4 and a nuclear loc-
alization signal, which are linked with flexible glycine
stretches. The p53-responsive element linked to the
GAL4 upstream activating sequence was efficiently
transferred by the vehicle protein into nuclei of prim-
ary cultures of neuronal cells, embryonic stem cells
and various human normal cells. Transcriptional
activation of p21
WAF1/CIP1 and Bax by p53 on expo-
sure to cisplatin was completely blocked by introdu-
cing the p53decoy oligonucleotide.Thus, the system
developed in the present study can be a convenient
and powerful tool for specifically disrupting the
function of DNA-binding proteins in culture.
INTRODUCTION
Functional inactivation of speciﬁc gene products is a powerful
and promising tool not only for studying biological relevance
of a given gene but also for developing target gene-based
therapeutic measures. The ‘loss-of-function’ of a gene can be
achieved by a number of different approaches, including the
expression of a dominant negative form of proteins, intracel-
lular introduction of speciﬁc antibodies, antisense oligonuc-
leotides, siRNA and decoy oligonucleotides for DNA-binding
proteins (1–4). Among those approaches, the decoy oligo-
nucleotide method is advantageous in terms of promptness
of effects, simplicity and easiness in handling (5,6).
In cells, gene expression is principally regulated at the
transcriptional level by DNA-binding proteins known as tran-
scription factors. Introduction of an excess amount of a DNA
segment harboring a cis-element into cells results in functional
sequestering of the counterpart-transacting factor from acting
on the endogenous target promoters. Thus, decoy oligonuc-
leotides, including those for NF-kB, E2F and AP-1, have been
successfully used in vivo as well as in vitro (7–13).
Many attempts have been made to improve the efﬁciency
of the decoy oligonucleotide method. Phosphothioation was
shown to stabilize decoy oligonucleotides introduced into
cells (7,14). Also, oligonucleotides became more stable when
both ends were locked by adding an extra 20-O, 40-C-methy-
lene bridge to the ribose ring (15). Ahn et al. (16) showed that
circular dumbbell oligonucleotides were more resistant to exo-
nuclease, exhibiting more prolonged effects. Another problem
to be overcome is how to efﬁciently introduce decoy oligo-
nucleotides into cells. The most frequently used method to
introduce oligonucleotides into cells is liposome-mediated
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doi:10.1093/nar/gni088transfection and its utility has been shown in many biological
contexts. Recently, however, Bene et al. (17) showed that an
AP-1 decoy oligonucleotide remained mainly in the peri-
nuclear cytoplasm and exhibited a marginal biological effect
when transfected using a liposome-mediated method. A sim-
ilar phenomenon was observed in vivo by Griesenbach et al.
(18). To address this problem, we designed a new vehicle
protein to facilitate the efﬁcient introduction of decoy oligo-
nucleotides into cell nuclei. Here, we show that the vehicle
protein efﬁciently transported a decoy oligonucleotide for
p53 into nuclei of various cell types, including primary neur-
onal cells and mouse embryonic stem (ES) cells, resulting in
complete suppression of transcriptional activity of p53.
MATERIALS AND METHODS
Cell culture
A p53-proﬁcient human colon cancer cell line, HCT116, was
a kind gift from Dr B. Vogelstein (Johns Hopkins University),
and a p53-deﬁcient human prostate cancer cell line, PC3, was
provided by ATCC (Rockville, MD). A normal human ﬁbro-
blast strain, OUMS-36, was provided by Dr M. Namba (Niimi
College). DMEM (Nissui, Tokyo, Japan) and HAM’S F-12 K
medium were used for HCT116 and OUMS-36 cells and for
PC3 cells, respectively, with a supplement of 10% fetal bovine
serum(FBS).Normalneonatalhumanepidermalkeratinocytes
(NHKs) (Cascade Biologics, Portland, OR) were cultured in
an animal-product free medium, EpiLife, with a growth sup-
plement, V2. The mouse ES cell line CGR8 (19) was a kind
gift from Dr H. Tanba (Osaka University), and the cells were
cultured in DMEM supplemented with 15% FBS, 1% non-
essential amino acids solution (Invitrogen, Carlsbad, CA),
nucleotide stock solution (30 mM each of adenosine, guano-
sine, cytidine and uridine, and 10 mM thymidine), 110 mM
2-mercapto ethanol and 1000 U/ml mouse leukocyte inhibi-
tory factor (Sigma). Primary cultures of adult rat hepatocytes
and embryonic mouse and rat brain cells were performed as
described previously (20,21). DMEM supplemented with
10 mM dexamethasone and 10 mg/ml insulin and DMEM
with 10 mM dibutyryl cAMP (Sigma) and 1 mM theophylline
(Sigma) were used for the hepatocytes and brain cells, respect-
ively. Human leukocytes were prepared from peripheral blood
using a leukocyte puriﬁcation kit (LeucoSep; Greiner Bio-one,
Tokyo, Japan).
Plasmid constructs
A DNA fragment encoding 7 glycine residues (7G) and
7 arginine residues (7R) was synthesized and integrated
into a downstream site of glutathione-S-transferase (GST)
of the vector pGEX6P1 (Amersham Biosciences). The result-
ing plasmid was designated as pGEX6P1-7R. A PCR was
performed with a forward primer encoding 7G and a 50-region
of the DNA-binding domain (DB) of GAL4 (22) (50-
ccggaattccggggaggaggaggaggaggaggaatgaagctactgtcttctat-30)
and a reverse primer encoding a 30-region of GAL4 DB, 3G,
and the nuclear localization signal of SV40 [nuclear localiza-
tionsignal(NLS):PKKKRKV(23)](50-tcccccgggggacacctttc-
gcttcttctttggtcctcctccaatcgatacagtcaactgtc-30) using a plasmid
harboring GAL4 as a template. The ampliﬁed fragment was
inserted into pGEX6P1 and pGEX6P1-7R to construct
pGEX6P1-GAL4-NLS and pGEX6P1-7R-GAL4-NLS,
respectively.
To make a decoy oligonucleotide for p53, a DNA fragment
encoding the GAL4 upstream activating sequence [UAS;
cggagtactgtcctccg; (24)] and two copies of a p53-responsive
element (50-tacagaacatgtctaagcatgctgggg-30) in tandem with
EcoRI linkers at both end (altogether 95 bp in length)
was synthesized and integrated into the vector pDNR-CMV
(Clontech). To prepare a mutant oligonucleotide, 50-catg-30
shown above in bold was changed to 50-tcgc-30.
Nucleotide sequences of these constructs were veriﬁed by
sequencing.
Purification of recombinant proteins
pGEX6P1, pGEX6P1-7R, pGEX6P1-GAL4-NLS and
pGEX6P1-7R-GAL4-NLS were transfected into Escherichia
coli [BL21-Codon Plus-(DE3)-RIL; Stratagene] to produce
proteins composed of GST only, GST-7G-7R, GST-7G-
GAL4-3G-NLS and GST-7G-7R-7G-GAL4-3G-NLS, respect-
ively. For puriﬁcation of nucleic acid-free recombinant
proteins, the respective E.coli was frozen and thawed twice
in a buffer (20% sucrose, 0.6 M NaCl, 1 mM phenylmethly-
sulfonyl ﬂuoride, 10 mM Tris–HCl, pH 7.5) followed by son-
ication for 10 min (Soniﬁer 250, Bransonn). Contaminated
nucleic acid was degradated by incubating with 30 mg/ml
DNase I (Sigma), 30 mg/ml RNase A (Sigma) and 10 mM
MgCl2. After sonicating again, the lysates were centrifuged
for removing insoluble debris and each protein was puriﬁed
fromthesupernatantsusingaSephadex4Bcolumn(Amersham
Biosciences).Forthepreparationofaproteincomposed of7G-
7R-7G-GAL4-3G-NLS, GST-7G-7R-7G-GAL4-3G-NLS was
cleaved with PreScission protease (Amersham Biosciences)
and the GST was removed using the Sephadex 4B column.
Introduction of oligonucleotides into cells
Oligonucleotides were introduced into cells by applying in
a mixture with the vehicle proteins in serum-free media for
1 h. Lipofection was performed using Lipofectamine 2000
(Invitrogen).
Labeling and monitoring the fate of the decoy
oligonucleotides
The wild-type or mutant decoy oligonucleotide for p53 was
prepared by restricting plasmid DNAs and puriﬁed by an agar-
ose electrophoresis. Labeling of the decoy oligonucleotides
was performed using [g-
32P]ATP (HAS, Budapest, Hungary)
and T4 polynucleotide kinase (New England BioLabs,
Beverly, MA). For monitoring the fate of the labeled decoy
DNA in cells, the introduced oligonucleotides were recovered
by extracting cells with a hypotonic buffer (10 mM KCl, 0.1%
Triton X-100, 5 mM EDTA, 10 mM Tris–HCl, pH 8.0)
followed by another extraction with a buffer (500 mM KCl,
1.0% Triton X-100, 5 mM EDTA, 10 mM Tris–HCl, pH 8.0).
The combined extracts were subjected to a conventional
phenol–chloroform method.
Intracellular localization of the vehicle protein and
oligonucleotides
The puriﬁed recombinant proteins and decoy DNA were
labeled with Cy3 and Alexa Fluor 488 using a Cy3 Antibody
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Fluor 488 Nucleic Acid Labeling Kit (Molecular Probes,
Eugene, OR), respectively. Intracellular localization of the
introduced molecules in living and ﬁxed cells were observed
using a ﬂuorescent microscope (IX71-22FL/PH; CCD camera,
DP50; objective lens, LCPlan F1 40·; Olympus) and a laser-
scanning microscope (Axioplan 2; objective lens, Plan-
Apocgomat 63· 1.4 oil DC; Carl Zeiss MicroImaging),
respectively.
Western blot analysis
Immunoblotting was performed using a rabbit anti-GST
antibody (Amersham Biosciences), a mouse anti-GAL4
(DB) antibody (Santa Cruz Biotechnology, Santa Cruz,
CA), a mouse anti-human p53 antibody (Santa Cruz Biotech-
nology), a rabbit anti-human p21
WAF1/CIP1 antibody (Santa
Cruz Biotechnology), a rabbit anti-human Bax antibody
(Upstate Biotechnology, Lake Placid, NY) or a mouse anti-
human tubulin antibody (Sigma), followed by the application
of a horseradish peroxidase-conjugated anti-mouse or anti-
rabbit IgG antibody (Cell Signaling Technology Inc., Beverly,
MA). Positive signals were visualized using a chemilumines-
cence system (ECL plus, Amersham Biosciences).
Northern blot analysis
Total RNA was isolated by the acid guanidinium thiocyanate/
phenol–chloroform method. Northern blot analysis was per-
formed under conventional conditions. Brieﬂy, 20 mg RNA
of each sample was fractionated in a 1.0% agarose gel and
transferred to a Nytran Plus nylon membrane (Amersham
Biosciences). Probes synthesized from entire cDNAs of
human p21
WAF1/CIP1 and GAPDH were used.
Electrophoresis mobility shift assay
Electrophoresis mobility shift assay (EMSA) was performed
under conditions similar to those described by Nakano et al.
(25). Brieﬂy,
32P-labeled decoy DNA probes (0.5 mg) were
incubated with 0.1–2 mg of crude nuclear extracts of HCT116
or PC3 cells in a reaction mixture (20 ml) containing 60 mM
KCl, 5 mM MgCl2, 0.1 mM EDTA, 1 mg poly(dI–dC), 1 mM
DTT,5%glyceroland20mM HEPES,pH7.9.Forasupershift
assay, 2 mg of puriﬁed vehicle proteins and/or 0.5–2 mgo fa
mouse anti-human p53 antibody (Santa Cruz Biotechnology)
were added to the reaction mixture. DNA–protein complexes
were then separated by electrophoresis in a 5% polyacrylam-
ide gel under non-denaturing conditions.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed according
to a method described previously (26). In brief, HCT116
cells were cross-linked by adding formaldehyde to 1% ﬁnal
concentration, and p53–DNA complex was immuno-
precipitated with a mouse anti-human p53 antibody (Santa
Cruz Biotechnology). A p53-responsive region in the
p21
WAF1/CIP1 promoter was ampliﬁed using a forward primer,
50-gtgcagacagcagtggggcttagag-30 and a reverse primer,
50-cagaacccaggcttggagcagctac-30.
RESULTS
Design of experiments
Figure 1 shows the design of a method to efﬁciently introduce
a decoy oligonucleotide into nuclei. Two tandem p53-
responsive elements (p53RE) for sequestering p53 protein
were linked to the yeast UAS sequence, which binds to
GAL4 in the vehicle protein. The vehicle protein (GST-
7GR-Ga-NLS; 45.8 kDa) is composed of GST, 7G residues,
7 arginine residues, 7 glycine residues, the DB of GAL4,
3 glycine residues and the NLS from the N-terminal side.
The poly-arginine and NLS facilitate the incorporation of
proteins into cells and nuclei, respectively (23,27,28). GST
isusedforthe puriﬁcationofthe recombinantproteinsandalso
for promoting cellular incorporation of proteins (Figure 4B).
The glycine stretches provide ﬂexible linkages between each
domain. The oligonucleotide was expected to be efﬁciently
transferred to nuclei by the help of the vehicle protein,
resulting in the inhibition of p53 function by sequestering it.
Specific binding of the decoy oligonucleotide to p53
We ﬁrst examined whether the decoy oligonucleotide binds to
the vehicle protein and p53. When the labeled oligonucleotide
was incubated with the vehicle protein GST-7GR-Ga-NLS
in vitro, it dose dependently bound to the protein as demon-
strated by EMSA, whereas it showed no binding activity to
the protein lacking GAL4 and NLS domains (GST-7GR)
(Figure 2A). The oligonucleotide could simultaneously bind
to p53 proteinin a nuclear extract prepared from HCT116 cells
as well as to the vehicle protein (Figure 2B). Speciﬁcity of the
binding was conﬁrmed by supershift of the band observed
when an antibody against p53 was added to the reaction
Figure 1. A schematic diagram of the method to introduce a decoy oligo-
nucleotide into nuclei. The oligonucleotide is composed of UAS and two
p53-responsive elements in tandem (p53RE). The vehicle protein (GST-
7GR-Ga-NLS) is composed of GST, 7 glycine residues, 7 arginine residues
(7R), 7 glycine residues, the DNA-binding domain (DB) of GAL4, 3 glycine
residues and an NLS. UAS is for binding to GAL4 in the vehicle and p53RE
sequesters p53 protein. 7R and GST promote the incorporation of the protein
into cells. GST is also used for purification of the protein.
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ated with a nuclear extract from p53-deﬁcient PC3 cells.
To examine whether the oligonucleotide bound to p53 protein
within cells, the oligonucleotide was introduced into HCT116
cells by means of lipofection, GST-7GR, or GST-7GR-Ga-
NLS, and the vehicle proteins recovered using glutathione
beads from cell extracts were analyzed by western blotting
(Figure 2C). p53 protein was detected only when the oligo-
nucleotides containing the wild-type p53RE were applied with
GST-7GR-Ga-NLS. These results indicate that the oligo-
nucleotide designed in the present study can simultaneously
bind to p53 as well as the vehicle GST-7GR-Ga-NLS in vitro
and in cells.
Efficient introduction of the decoy oligonucleotide into
different types of cells, particularly into nuclei
When GST-7GR-Ga-NLS was applied to HCT116 cells, the
vehicle protein was ﬁrst detected in the cells at 30 min and the
amount slightly increased up to 360 min after the application
(Figure 3A). Incorporation of the labeled oligonucleotide by
GST-7GR-Ga-NLS depends on the dose of the vehicle protein
as assayed at 7 h after application (Figure 3B). Twenty micro-
grams of GST-7GR-Ga-NLS was sufﬁcient to attain the
maximum introduction to 10
4 HCT116 cells cultured in 1 ml
of medium. Under these conditions,  10% of the 200 ng
oligonucleotide added to the medium was incorporated into
the cells. Although lipofection could also efﬁciently introduce
the oligonucleotide into the cells, most of the incorporated
oligonucleotides were found in the perinuclear cytoplasm
(Figure 3C, top panels) in accordance with the report by
Bene et al. (17). In contrast, the oligonucleotide was detected
mostly in nuclei when introduced using GST-7GR-Ga-NLS
(Figure 3C, bottom panels). The preferential introduction of
the decoy oligonucleotideintonucleibyGST-7GR-Ga-NLS in
comparison with lipofection was also observed in NHK cells
and mouse ES cells (Figure 4A). Applicability of the present
method to a wide variety of cells was conﬁrmed by western
blotting (Figure 4B) and by the determination of radioact-
ivity after the application of the labeled oligonucleotide
(Figure 4C). GST-7GR-Ga-NLS facilitated the incorporation
of the oligonucleotide in primary cultures of mouse and rat
brain neuronal cells and rat hepatocytes, in normal human
keratinocytes, ﬁbroblasts (OUMS-36) and leukocytes, and
in mouse ES cells. Efﬁciency of the cellular incorporation
was not affected by cell density in OUMS-36 (Figure 4C,
lower right panel). Either GST or 7-arginine stretch alone
could not promote the protein transduction (Figure 4B).
Figure 2. Binding of the decoy oligonucleotide to the vehicle protein. (A) Binding of the decoy oligonucleotide was assessed by EMSA. Labeled decoy nucleotide
wasincubatedwithincreasingamountsofthevehiclepeptidedescribedinthelegendtoFigure1(GST-7GR-Ga-NLS)orthatlackingGAL4andNLS(GST-7GR)and
analyzed by electrophoresis. (B) Binding of the decoy nucleotide not only with the vehicle protein but also with p53 protein in a nuclear extract. Labeled decoy
nucleotidewasincubatedwithindicatedproteinsand increasingamountsofnuclear extractpreparedfrom p53-proficient HCT116cells.In sometubes,anantibody
against p53 was added. Arrowheads indicate the following positions: B1, the probe only; B2, the probe bound to p53; B3, the probe bound to p53 and the vehicle
protein; and B4, the probe bound to p53, the vehicle protein and p53 antibody. 7GR-Ga-N and 7GR correspond to GST-7GR-Ga-NLS and GST-7GR, respectively.
(C)Bindingofthedecoyoligonucleotidewithp53incells.Thedecoyoligonucleotide(wild-typeormutated)wasappliedbymeansoflipofection(Lipof),GST-7GR
or GST-7GR-Ga-NLS to HCT116 cells treated with cisplatin (10 mg/ml, 6 h) or not treated. Introduced proteins were recovered from cell extracts using glutathione
beads and analyzed by western blotting using an antibody against GST (upper panel) or an antibody against p53 (lower panel).
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ported oligonucleotides into nuclei (data not shown).
Inhibition of the function of p53
Biological relevance of the decoy oligonucleotide introduction
was studied by examining the activity of p53 in transcriptional
regulation. The wild-type or mutated decoy oligonucleotide
was applied to HCT116 cells with GST-7GR-Ga-NLS. One
hour later, cisplatin (10 mg/ml) was added to the medium
and the cells were harvested for analysis 6 h after the oligo-
nucleotide application. By treatment with cisplatin, the
protein level of p53 was elevated and this was not affected
by any treatments for the introduction of oligonucleotides
(Figure 5A). In accordance with the reported ﬁndings that
the p21
WAF1/CIP1 and Bax promoters were activated on
exposure to cisplatin (29,30), we detected increased amounts
of p21WAF1/CIP1 and Bax proteins in the cells treated with
cisplatin. The induction of both proteins was completely sup-
pressed when the cells were pretreated with the wild-type
oligonucleotide and GST-7GR-Ga-NLS (Figure 5A). To
obtain some mechanistic insights, we examined bind-
ing of p53 to the p21
WAF1/CIP1 promoter by a chromatin
immunoprecipitation assay. p53 protein was activated to
bind to the p21
WAF1/CIP1 promoter by treatment with cisplatin
and the binding was completely suppressed when the oligo-
nucleotide harboring the wild-type p53-responsive element,
but not that having the mutated element, was introduced by
GST-7GR-Ga-NLS (Figure 5B). Although lipofection could
introduce the oligonucleotide with efﬁciency comparable with
that by GST-7GR-Ga-NLS (Figure 3B), the induction of
p21
WAF1/CIP1 and Bax protein (Figure 5A) and the binding
p53 to the p21
WAF1/CIP1 promoter (Figure 5B) were not appre-
ciably affected. This indicates that transportation of the decoy
oligonucleotide to the nuclei and not to the cytoplasm is cru-
cial for modulating function of transacting factors in cells.
Stability of the decoy oligonucleotide in cells
Finally, we examined stability of the incorporated oligonuc-
leotide and duration of the functional sequestering of p53
protein. Labeled decoy oligonucleotide was introduced into
HCT116 cells or NHK cells, and the radioactivity recovered
from the cells was monitored by autoradiography after elec-
trophoresis. As shown in Figure 6A, the intracellular oligo-
nucleotide levels remained essentially unchanged until 12 h,
Figure 3. Introductionofthedecoynucleotideintocellsbythevehicleprotein.(A)Timecourseofcellularuptakeofthevehicleprotein.GST-7GR-Ga-NLS(20mg)
was applied to HCT116 cells and was recovered from cell extracts using glutathione beads at various times after the application. (B) Introduction of the decoy
oligonucleotide into HCT116 cells by the vehicle proteins. Radioactivity in cells and medium was determined 6 h after the application of labeled decoy
oligonucleotide to HCT116 cells by lipofection (Lipofect), GST-7GR (50 mg/ml) or indicated amounts of GST-7GR-Ga-NLS. (C) Introduction of the decoy
oligonucleotide into cell nuclei. The decoy oligonucleotide labeled with Alexa Fluor 488 (in green) was applied to HCT116 cells with the vehicle proteins labeled
withCy3(inred)andobserved6hafterapplication.Thecellswereobservedbyaconfocallasermicroscopeataplanehorizontallycuttinginthemiddlepartofcells.
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around 24 h, and decreased to an undetectable level around
48 h after the application in both cell types. Duration of the
biological effects of the introduced oligonucleotide was stud-
ied in NHK cells because HCT116 cells underwent apoptotic
cell death by treatment with cisplatin. NHK cells were treated
with cisplatin 1 h after the introduction of the wild-type or
mutated decoy oligonucleotide into the cells, and then
p21
WAF1/CIP1 mRNA level was monitored (Figure 6B). In the
cells exposed to the mutated p53 decoy oligonucleotide,
p21WAF1/CIP1 mRNA was induced and remained at similar
levels during the observation period of 72 h. Introduction
of the wild-type p53 decoy oligonucleotide completely sup-
pressedtheinductionofp21WAF1/CIP1mRNAupto24h.Alow
level of p21
WAF1/CIP1 mRNA was detected at 36 h and the
amount had increased to a level comparable with that of
untreated cells at 48 h. This kinetics accorded well with the
amount the decoy oligonucleotide in the cells (Figure 6A).
Figure 4. Efficientintroductionof the decoy oligonucleotide into diversetypes of cells.(A) The decoy oligonucleotide labeledwith Alexa 546 (in red) was applied
with the vehicle protein or by lipofection onto normal human keratinocytes (NHKs) or mouse ES cells and observed by a confocal laser microscope. Nuclei were
stained with SYBR Green (in green). (B) Proteins of different structural compositions were applied to various types of cells, and the media and cell extracts were
analyzed by western blotting using anti-GAL4 antibody. GST-7GR-Ga-NLS, the complete vehicle protein; GST-Ga-NLS, a vehicle protein lacking 7 arginine
residues; 7GR-Ga-NLS, a vehicle protein lacking GST. (C) Radiolabeled decoy oligonucleotide was applied to various types of cells with the complete vehicle
protein(GST-7GR-Ga-NLS)ora proteinlackingGAL4andNLS(GST-7GR),andradioactivityincell extractswasdetermined.Lowandhighindicatelow-density
and high-density cultures of OUMS-36, human normal diploid fibroblasts.
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In the present study, we designed a vehicle protein for efﬁcient
introduction of decoy nucleotides into cell nuclei. It is com-
posed of GST, 7 arginine residues, the DB of GAL4 and the
NLS of SV40 large T antigen, which are linked with ﬂexible
glycine stretches. The present system has the following
advantages:
(i) It is applicable for a broad variety of cells, including
primary cultured cells and ES cells (Figure 4B and C).
(ii) It is highly efficient in terms of transduced cell rate
(practically 100%) (Figures 3C and 4A).
(iii) It is efficient in terms of targeting the oligonucleotide for
cell nuclei (Figure 3C), which is a prerequisite for inter-
fering with transcriptional activation (Figure 5A and B).
(iv) It is prompt and efficient in exhibiting the interfering
function (Figures 3A and 5A).
(v) It is applicable for other DNA-binding proteins whose
target elements are known.
(vi) It is easy to use and economical. The recombinant vehicle
protein can be produced in a large amount and easily
purified and stocked.
In most studies on the effect of decoy oligonucleotides,
lipofection has been used for transducing oligonucleotides
into cells. Efﬁciency of transfection by lipofection is high
compared with the efﬁciencies of other DNA transfection
methods. However, the efﬁciency largely depends on cell
types. Another potential shortcoming of lipofection is that it
does not directly help nuclear translocation of the oligonuc-
leotide, which is critical for interfering with the function of
transcription factors (17). In the present study, we attempted
to actively transport oligonucleotide into nuclei. As shown in
Figure 3C, nearly half of the incorporated oligonucleotide
was found in the nuclei, a much larger proportion than that
observed in cells transduced by lipofection.
The GST and 7 arginine residues cooperatively facilitate
to introduce the protein into cells (Figure 4B). Namiki et al.
(31) reported that the ﬂuorescent-dye-labeled GST from
Schistosoma japonicum penetrated into mammalian cells
even when conjugated to a short-peptide load. In the present
system, GST derived from yeast alone could not promote
the protein transduction (Figure 4B). A number of different
molecules are known to transduce proteins into cells. TAT
domain derived from human immunodeﬁciency virus (32)
and 11-arginine stretch (27,28) are widely used for protein
transduction. Covalent conjugation of proteins with polyethyl-
enimine is another potent measure for protein transduc-
tion (33,34). The strong cation charge of polyethylenimine,
however, results in non-speciﬁc binding to DNA and is
inappropriate for the present purpose.
p53 is known to exert its transactivation capacity through
forming a homotetramer (35). At present, it is not clear
whether p53 protein formed a tetramer complex in the pres-
ence of the decoy oligonucleotides under the present condi-
tions. Since the DNA-binding domain resides in the central
part of p53 protein and is apart from the C-terminal tetra-
merization domain, the p53 protein bound with the oligo-
nucleotides could still form homotetramers. However, the
vehicle protein that most likely remains combined with the
oligonucleotides may interfere with the association of p53
protein. Chan et al. (36) showed that a mutant p53 defective
in DNA binding, unlike p53 mutated in the transactiva-
tion domain, was inefﬁcient in exhibiting the dominant
negative effect. This indicates inefﬁciency in inhibiting the
Figure 5. Biological effects of introduction of the decoy oligonucleotide.
(A) A decoy oligonucleotide carrying wild-type p53RE or mutated p53RE
was introduced into HCT116 cells with or without cisplatin treatment. Cell
extracts prepared 6 h after the application were analyzed for indicated proteins
by western blotting.Arrowhead indicates the critical lane showing suppression
of the function of p53. (B) Chromatin immunoprecipitation assay for p53
protein bound to the p21
WAF1/CIP1 promoter. The cells were treated under
conditions similar to those described in (A) and immunoprecipitates with
anti-p53 antibodywere subjected to PCR amplification using primerscovering
p53 RE in the p21
WAF1/CIP1 promoter. PC3 was used as a negative control
because of its deficiency of p53. 7GR-Ga-N and 7GR correspond to GST-
7GR-Ga-NLS and GST-7GR, respectively.
Figure 6. Stability of the decoy oligonucleotide in cells. (A) Radiolabeled
decoy oligonucleotide was applied with GST-7GR-Ga-NLS to HCT116 or
NHKcellsandamountsoftheintactoligonucleotide(95bpinlength)recovered
from the cells was monitored by electrophoresis and autoradiography.
(B) Northern blot analysis for p21
WAF1/CIP1 mRNA after the introduction of
the oligonucleotides. NHK cells were subjected to application of the wild-type
or mutated decoy oligonucleotide and GST-7GR-Ga-NLS at the time point 0,
exposed to cisplatin (10 mg/ml) from 1 h later and harvested at indicated time
points. GAPDH was used as a control for applied amounts of RNA.
PAGE 7 OF 9 Nucleic Acids Research, 2005, Vol. 33, No. 9 e88transactivation capacity of p53 by blocking its DNA-binding
activity. The number of p53 molecules per cell was estimated
to be several hundred thousand at most (37). In the present
study,  10% of the applied amount of the oligonucleotide was
incorporated into cells (Figure 3). At the lowest estimate,
about one hundred excess molecules of the oligonucleo-
tide were present in cell nuclei in comparison with that of
p53 protein, being sufﬁcient to completely sequester the
transacting factor.
The present method can be used not only for studying the
functions of transacting factors but also the function of any
proteins that exert their functions through binding to a DNA
region in a sequence-speciﬁc manner. It can also be used for
the determination of DNA elements relevant to transcriptional
regulation among candidate segments in the promoter region.
With the features described, the present method could cer-
tainly be a convenient and powerful tool for studying the
functions of DNA-binding proteins in culture, though not
suitable for using in vivo.
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